

Evaluation of the Triglyceride-Glucose Index with Different Generations of Beta-Adrenergic Blockers

Farklı Nesil Beta-Adrenergik Blokerlerde Trigliserit-Glukoz İndeksinin Değerlendirilmesi

Demet Erciyes¹, Cennet Yıldız², Atakan Arpaç², Fatma Nihan Turhan Çağlar²

¹Demiroğlu Bilim University Florence Nightingale Hospital, Department of Cardiology, İstanbul, Türkiye

²University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Cardiology, İstanbul, Türkiye

ABSTRACT

Background: Beta-blockers (β -blockers) work by blocking β -adrenergic receptors and differ in their metabolic effects and side effects. We aimed to compare the metabolic effects of different generations of β -blockers by evaluating the triglyceride-glucose (TyG) index in patients treated with this group of drugs.

Materials and Methods: Subjects using β -blockers were divided into three groups according to first-generation, second-generation, and third-generation β -blockers. The TyG index values of the subjects were calculated.

Results: There were no differences in age, sex, presence of hypertension, coronary artery disease, or use of medications among the three groups. Glucose, triglycerides, hemoglobin A1c and TyG index were significantly different between three groups of patients. A post-hoc analysis revealed group differences between the third-generation, second-generation, and first-generation, β -blockers. Patients taking third-generation β -blockers had the lowest TyG index and the lowest triglyceride and glucose levels. Univariable and multivariable linear regression analyses showed that age and the β -blocker group were independent predictors of TyG index values.

Conclusion: The use of third generation β -blockers was associated with better metabolic profiles.

Keywords: Triglyceride, glucose, β -blocker, metabolic profile

ÖZ

Amaç: Beta-blokerler (β -blokerler) β -adrenergik reseptörleri bloke ederek çalışır ve kardiyovasküler hastalıklarda en sık kullanılan ilaçlar arasındadır. Metabolik etkileri ve yan etkileri bakımından farklılık gösterirler. Bu çalışmada amacımız β -blokerler ile tedavi edilen hastalarda trigliserid-glukoz indeksini (TyG) değerlendirerek farklı nesil β -blokerlerin metabolik etkilerini karşılaştırmayı amaçladık.

Gereç ve Yöntemler: β -bloker kullanan hastalar birinci, ikinci ve üçüncü nesil β -blokerlere göre üç gruba ayrıldı. Bu hastaların TyG indeks değerleri hesaplanarak karşılaştırıldı.

Bulgular: Üç grup arasında yaş, cinsiyet, hipertansiyon varlığı, koroner arter hastalığı veya ilaç kullanımı açısından fark yoktu. glukoz, trigliserit, hemoglobin A1c ve TyG indeksi üç hasta grubu arasında anlamlı derecede farklıydı. Post-hoc analiz, üçüncü nesil, ikinci nesil ve birinci nesil β -blokerler arasında grup farklılıkları olduğunu ortaya koydu. Üçüncü nesil β -bloker kullanan hastalar en düşük TyG indeksinin yanı sıra en düşük trigliserit ve glukoz seviyelerine sahipti. Tek değişkenli ve çok değişkenli doğrusal regresyon analizleri, yaşın ve β -bloker grubunun TyG indeks değerlerinin bağımsız belirleyicileri olduğunu gösterdi.

Sonuç: Üçüncü nesil β -blokerlerin kullanımı daha iyi metabolik profil ile ilişkilidir.

Anahtar Kelimeler: Trigliserid, glukoz, β -bloker, metabolik profil



Address for Correspondence: Cennet Yıldız, University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Cardiology, İstanbul, Türkiye

E-mail: cennet_yildiz@live.com **ORCID ID:** orcid.org/0000-0003-2456-3206

Received: 06.10.2024 **Accepted:** 15.07.2025 **Epub:** 02.09.2025 **Publication Date:** 30.09.2025

Cite this article as: Erciyes D, Yıldız C, Arpaç A, Turhan Çağlar AN. Evaluation of the triglyceride-glucose index with different generations of beta-adrenergic blockers. Hamidiye Med J. 2025;6(3):128-134



Copyright© 2025 The Author. Published by Galenos Publishing House on behalf of University of Health Sciences Türkiye, Hamidiye Faculty of Medicine. This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

Introduction

Beta-blockers (β -blockers) exert their actions by blocking β -adrenergic receptors (1). However, they differed in terms of metabolic actions and side effects. Traditionally, β -blockers are divided into three groups with respect to their pharmacological features. First generation β -blockers non-selectively act on β -1 and β -2 receptors, whereas second generation β -blockers show greater affinity for β -1 receptors. More recently introduced third generation β -blockers differ by their cardioselective actions and have additional vasodilating properties by blocking alpha (α)-1 and activating β -3-adrenergic receptors (1). Various studies have investigated the metabolic adverse effects of these drugs. Metoprolol, atenolol, and propranolol, considered as conventional β -blockers, have negative effects on insulin sensitivity and glucose metabolism. They are found to be linked to heightened risk of new-onset diabetes mellitus (2). On the contrary, β -blockers with vasodilating actions have more favorable cardiometabolic effects (3,4).

Insulin resistance, reduced response to the circulating insulin, is closely associated with two common conditions, namely, metabolic syndrome and type 2 diabetes mellitus (5). Insulin, by affecting the insulin receptor tyrosine kinase, brings about a series of reactions in different cell types such as glucose uptake in skeletal muscle, inhibition of gluconeogenesis in liver, and suppression of lipolysis in adipocytes (6). Insulin resistance with resultant hypertriglyceridemia, low levels of high-density lipoprotein-cholesterol (HDL-C), high blood pressure level, proinflammatory status, and endothelial dysfunction make a large contribution to cardiovascular disease pathogenesis (7-11). Several methods have been used to diagnose insulin resistance with different sensitivities and complexities (12). The hyperinsulinemic-euglycemic glucose clamp is considered the best method (13) for the identification of insulin resistance, but it is expensive and requires expertise. The triglyceride-glucose (TyG) index is a novel biomarker that has been suggested to predict the insulin resistance status of the body in patients with or without diabetes (14,15). Clinical significance of this index has been shown in several diseases such as acute and chronic coronary syndromes, heart failure, cerebrovascular disease, and populations with high cardiovascular risk (16-20). The present study was aimed at measuring the metabolic effects of different generations of β -blockers by evaluating the TyG index in patients who were under treatment with this group of drugs.

Materials and Methods

We retrospectively screened the hospital files of the patients who applied to our cardiology clinic at a tertiary care hospital. We enrolled consecutive patients who met the inclusion criteria applied in our outpatient clinic from 1 June 2022 to 1 June 2023. Patients diagnosed with acute coronary syndrome, diabetes mellitus, thyroid diseases, hepatic or renal failure, malignancy, or inflammatory diseases were excluded from the study. Additionally, those using triglyceride-lowering drugs were not included. Patients' clinical characteristics, demographic features and biochemical variables were obtained from the hospital records. After the application of exclusion criteria 712 patients were enrolled in the study. Patients were using six different β -blockers, namely metoprolol, atenolol, carvedilol, propranolol, bisoprolol, and nebivolol. We divided the patients into three groups according to first, second, and third generations of β -blockers. These groups consisted of 162, 303 and 242 patients, respectively.

Since our study was retrospective, we used the patients' blood results from the hospital's electronic records. We collected information regarding their glucose, triglyceride, and HgbA1c levels. The multiplication of glucose and triglyceride values was divided by two. The natural logarithmic transformation of the obtained results gave the TyG index values.

No artificial intelligence assistance was used during the preparation of the manuscript. The Demiroğlu Bilim University Clinical Research Ethics Committee approved the study (approval number: 44140529, dated: 31.01.2023) and it was conducted in accordance with the Declaration of Helsinki.

Statistical Analysis

The normality of the data was analyzed using the Kolmogorov-Smirnov test. Data showing normal distribution are expressed as the mean and standard deviation; otherwise, they are expressed as the median and interquartile range. A one-way analysis of variance or a Kruskal-Wallis test was used to compare the three groups, depending on the distribution of the data. Post-hoc analysis between groups was performed using Bonferroni correction. Categorical variables were compared by using a chi-square test. To identify predictors of the TyG index, a univariate linear regression analysis was performed. Because the TyG index was multicollinear with triglyceride and glucose levels in the presence of diabetes mellitus, we did not use these variables in the linear regression analysis. Variables

with statistically significant results were then entered into a multivariable linear regression analysis. A p-value less than 0.05 was considered significant.

Results

Median age of the study population was 59.00 (55.00-62.00) years, 366 51.4% of them were male, 367 51.5% of them were hypertensive, 365 51.3% patients had coronary artery disease, 252 35.4% of them were taking angiotensin converting enzyme inhibitors (ACE-I), 111 15.6% of them were taking angiotensin receptor blockers (ARB), 339 47.6% of them were using calcium channel blockers (CCB), 94 13.2% of them were using thiazide type diuretics and 365 51.3% of them were using statins. Median fasting glucose and triglyceride levels of the study group were 97.00 (94.00-100.00) mg/dL and 131.00 (120.00-147.00) mg/dL, respectively. Median hemoglobin A1c (HbA1c) and TyG index values were 5.70 (5.60-5.90) and 8.73 (8.64-8.90),

respectively. Average duration of β -blockers use was found to be 42.00 (24.00-53.00) months.

When comparing first, second, and third generation β -blockers, there were no differences in age, sex, presence of hypertension, coronary artery disease, or use of medications including ACE-I, ARB, CCB, thiazide-type diuretics, and statins. Glucose, triglyceride, HbA1c, and TyG index were significantly different between the three groups of patients. A post-hoc analysis revealed group differences between the third-generation, second-generation, and first-generation β -blockers. Patients taking third-generation β -blockers had the lowest TyG index, as well as the lowest triglyceride and glucose levels. Table 1 shows a comparison of the three groups' clinical and biochemical variables.

Univariable and multivariable linear regression analyses showed that age and the β -blocker group were independent predictors of TyG index values (Tables 2 and 3).

Table 1. Comparison of three groups

	First generation group (n=162)	Second generation group (n=303)	Third generation group (n=242)	p-value	
Age (years)	59.00 (55.00-62.00)	59.00 (56.00-63.00)	58.00 (54.00-62.00)	0.083	
Gender (n,%)				0.162	
Female	84 (51.9)	154 (50.8)	108 (43.7)		(Group 3-2) p=0.097
Male	78 (48.1)	149 (49.2)	139 (56.3)		(Group 3-1) p=0.107
					(Group 2-1) p=0.833
Hypertension (n,%)	86 (53.1)	164 (54.1)	117 (47.4)	0.261	
					(Group 3-2) p=0.117
					(Group 3-1) p=0.258
					(Group 2-1) p=0.830
CAD (n,%)	79 (48.8)	150 (49.5)	136 (55.1)	0.332	
					(Group 3-2) p=0.195
					(Group 3-1) p=0.212
					(Group 2-1) p=0.879
ACE-I (n,%)	66(40.7)	102 (33.7)	84 (34)	0.269	
					(Group 3-2) p=0.932
					(Group 3-1) p=0.167
					(Group 2-1) p=0.130
ARB (n,%)	23 (14.2)	44 (14.5)	44 (17.8)	0.489	
					(Group 3-2) p=0.295
					(Group 3-1) p=0.334
					(Group 2-1) p=0.924
Ca-channel blockers (n,%)	68 (42)	149 (49.2)	122 (49.4)	0.263	
					(Group 3-2) p=0.959
					(Group 3-1) p=0.141

	First generation group (n=162)	Second generation group (n=303)	Third generation group (n=242)	p-value	
					(Group 2-1) p=0.138
Thiazide diuretics (n,%)	18 (11.1)	39 (12.9)	37 (15)	0.515	
					(Group 3-2) p=0.476
					(Group 3-1) p=0.262
					(Group 2-1) p=0.581
Statin (n,%)	79 (48.8)	150 (49.5)	136 (55.1)	0.332	
					(Group 3-2) p=0.195
					(Group 3-1) p=0.212
					(Group 2-1) p=0.879
Glucose (mg/dL)	104.00 (95.00-109.00)	97.00 (93.00-99.75)	96.00 (93.00-98.00)	<0.001	
					(Group 3-2) p=0.002
					(Group 3-1) p<0.001
					(Group 2-1) p<0.001
Triglyceride (mg/dL)	136.12±17.19	133.94±17.00	127.81±11.43	<0.001	
					(Group 3-2) p<0.001
					(Group 3-1) p<0.001
					(Group 2-1) p<0.001
HbA1c	5.74±0.15	5.71±0.35	5.66±0.15	<0.001	
					(Group 3-2) p<0.001
					(Group 3-1) p<0.001
					(Group 2-1) p=0.001
TyG index	8.81±0.17	8.77±0.15	8.71±0.11	<0.001	
					(Group 3-2) p<0.001
					(Group 3-1) p<0.001
					(Group 2-1) p<0.001

ACE-I: Angiotensin converting enzyme inhibitor, ARB: Angiotensin receptor blocker, CAD: Coronary artery disease, HbA1c: Hemoglobin A1c, TyG index: Triglyceride-glucose index

	β	p-value	95% CI
Age	0.190	<0.001	0.004-0.009
Beta-blocker group	-0.481	<0.001	-0.122- -0.093
Gender	-0.042	0.269	-0.040-0.011
Hypertension	-0.030	0.427	-0.036-0.015

CI: Confidence interval, TyG index: Triglyceride-glucose index

	β	p-value	95% CI
Age	0.146	<0.001	0.003-0.007
Beta-blocker group	-0.467	<0.001	-0.119- -0.090

CI: Confidence interval, TyG index: Triglyceride-glucose index

Discussion

Our study showed that patients who were treated with the third generation of β -blockers had better metabolic profiles and lower values of the TyG index compared to patients who were treated with other types of β -blockers. Additionally, the use of third-generation β -blockers was an independent predictor of lower TyG values.

Both selective and non-selective β -blockers have been linked to the occurrence of insulin resistance and new-onset diabetes mellitus (21). Since this group of drugs is usually used in patients with high cardiovascular risk, their adverse effects have become important for clinicians. Over time, β -blockers with additional vasodilating and distinct metabolic activities have been developed, making them desirable in clinical practice.

Non-vasodilating β -blockers comprise first and second-generation β -blockers and their effects are mainly mediated through a decrease in cardiac output (22). They do not affect peripheral resistance, and administration of them is associated with unfavorable side effects. Several studies have been conducted in order to compare the metabolic side effects of different β -blockers. A post-hoc analysis of the Atherosclerosis Risk in Communities study has shown that patients who are treated with non-vasodilating β -blockers are at 28% higher risk of getting diabetes mellitus compared to patients who do not use them (21). Likewise, in the Losartan Intervention for Endpoint reduction study, the risk of diabetes mellitus development was 25% lower in patients who were treated with losartan in comparison to patients who were treated with atenolol (23). Carvedilol, a third generation β -blocker with non-selective β -adrenoceptor and α blocker activity, has been shown to improve insulin sensitivity and increase HDL-C levels (24). In a study in which carvedilol was compared with metoprolol, carvedilol has been associated with an increment of 8.5% in insulin sensitivity, where metoprolol decreased insulin sensitivity by up to 14% (24). In the GEMINI trial, carvedilol showed a more favorable metabolic effect in comparison to metoprolol. In that study, carvedilol decreased insulin resistance by 9.1%, whereas insulin resistance did not show any difference in patients treated with metoprolol (25). Nebivolol exerts its effects by blocking β -1 adrenergic receptors and increasing NO production, which might be the cause of more favorable metabolic effects of the drug (26). In comparison to nebivolol, metoprolol significantly reduced the insulin sensitivity index in patients with

metabolic syndrome (27). In a study conducted by Poirier et al. (28), atenolol reduced insulin sensitivity by 20%, and insulin sensitivity was not preserved with atenolol.

The TyG index has been validated in numerous studies as a superior tool for the prediction and identification of insulin resistance compared to the homeostasis model assessment of insulin resistance model (29). Its utility for both prognosis and diagnosis has been demonstrated across multiple studies. Higher TyG index levels were associated with an increased risk of chronic kidney disease, type 2 diabetes mellitus, diabetic retinopathy, non-alcoholic fatty liver disease, dementia, and ischemic stroke (30). Zhang and Hou (31) examined NHANES data to investigate the relationship between the TyG index and heart failure. They discovered a significant J-shaped dose-response relationship between the TyG index and heart failure risk. In a study of the general population, Liu et al. (32) analyzed the dose-response relationship between the TyG index and cardiovascular disease and mortality, reporting that elevated TyG index levels were linked to a higher incidence of coronary artery disease and myocardial infarction. In the present study, we investigated the TyG index in patients who applied to our cardiology outpatient clinic. Our results showed that patients who were treated with the third generation of β -blockers had significantly lower levels of TyG index in comparison to patients who were treated with other types of β -blockers. In our study, third-generation β -blockers consisted of nebivolol and carvedilol. Comparison of these drugs showed that the TyG index was not different ($p=0.352$). Second-generation β -blockers consisted of atenolol, metoprolol, and bisoprolol. When these drugs were compared in a separate analysis, the analysis showed that there was a difference between bisoprolol and atenolol groups. Patients using bisoprolol exhibit lowered TyG index values compared to patients who were using atenolol (8.81 ± 0.18 vs. 8.72 ± 0.12 , demonstrating a statistically significant difference, $p=0.004$).

Study Limitations

Our sample size was small, and the study was conducted on a single-center population. We did not conduct long-term follow-ups of the patients, so we could not assess the prognostic value of the TyG index or whether its prognostic utility was superior to that of glucose and triglyceride values.

Conclusion

Use of third generation β -blockers was associated with better metabolic profile.

Ethics

Ethics Committee Approval: The Demiroğlu Bilim University Clinical Research Ethics Committee approved the study (approval number: 44140529, dated: 31.01.2023) and it was conducted in accordance with the Declaration of Helsinki.

Informed Consent: All patients gave informed consent before study participation.

Footnotes

Authorship Contributions

Concept: D.E., A.A., Design: D.E., F.N.T.Ç., Data Collection or Processing: D.E., C.Y., A.A., F.N.T.Ç., Analysis or Interpretation: D.E., C.Y., A.A., F.N.T.Ç., Literature Search: C.Y., Writing: D.E., C.Y.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

- Oliver E, Mayor F Jr, D'Ocon P. Beta-blockers: historical perspective and mechanisms of action. *Rev Esp Cardiol (Engl Ed)*. 2019;72:853-862. [Crossref]
- do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β -blockers: history, class differences and clinical applicability. *Curr Hypertens Rev*. 2019;15:22-31. [Crossref]
- AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective β -blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. *Cardiovasc Drugs Ther*. 2022;36:959-971. [Crossref]
- Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Nebivolol in the treatment of arterial hypertension. *Basic Clin Pharmacol Toxicol*. 2019;125:189-201. [Crossref]
- Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. *Int J Mol Sci*. 2022;23:786. [Crossref]
- Youngren JF. Regulation of insulin receptor function. *Cell Mol Life Sci*. 2007;64:873-891. [Crossref]
- Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell*. 2000;6:87-97. [Crossref]
- Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. *J Int Med Res*. 2023;51:3000605231164548. [Crossref]
- Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021;143:e984-e1010. [Crossref]
- Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. *Int J Obes Relat Metab Disord*. 2004;28 Suppl 4:S58-S65. [Crossref]
- Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. *Front Endocrinol (Lausanne)*. 2024;15:1359255. [Crossref]
- Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal Transduct Target Ther*. 2022;7:216. [Crossref]
- Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. *Diabetes Care*. 2012;35:1605-1610. [Crossref]
- Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord*. 2008;6:299-304. [Crossref]
- Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solís RC, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. *Int J Endocrinol*. 2020;2020:4678526. [Crossref]
- Hao Q, Yuanyuan Z, Lijuan C. The prognostic value of the triglyceride glucose index in patients with acute myocardial infarction. *J Cardiovasc Pharmacol Ther*. 2023;28:10742484231181846. [Crossref]
- Luo JW, Duan WH, Yu YQ, Song L, Shi DZ. Prognostic significance of triglyceride-glucose index for adverse cardiovascular events in patients with coronary artery disease: a systematic review and meta-analysis. *Front Cardiovasc Med*. 2021;8:774781. [Crossref]
- Guo W, Zhao L, Mo F, Peng C, Li L, Xu Y, et al. The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: a retrospective cohort study. *Diabetes Res Clin Pract*. 2021;177:108786. [Crossref]
- Hoshino T, Mizuno T, Ishizuka K, Takahashi S, Arai S, Toi S, et al. Triglyceride-glucose index as a prognostic marker after ischemic stroke or transient ischemic attack: a prospective observational study. *Cardiovasc Diabetol*. 2022;21:264. [Crossref]
- Cai XL, Xiang YF, Chen XF, Lin XQ, Lin BT, Zhou GY, et al. Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk. *Cardiovasc Diabetol*. 2023;22:198. [Crossref]
- Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. *N Engl J Med*. 2000;342:905-912. [Crossref]
- Messerli FH, Grossman E. beta-Blockers in hypertension: is carvedilol different? *Am J Cardiol*. 2004;93:7B-12B. [Crossref]
- Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003. [Crossref]
- Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. *J Hypertens*. 1996;14:489-494. [Crossref]
- Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004;292:2227-2236. [Crossref]
- Marazzi G, Volterrani M, Caminiti G, Iaia L, Cacciotti L, Massaro R, et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. *Adv Ther*. 2010;27:655-664. [Crossref]
- Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. *Hypertension*. 2012;59:893-898. [Crossref]

28. Poirier L, Cl  roux J, Nadeau A, Lacourci  re Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. *J Hypertens*. 2001;19:1429-1435. [\[Crossref\]](#)
29. Luo P, Cao Y, Li P, Li W, Song Z, Fu Z, et al. TyG Index Performs Better Than HOMA-IR in Chinese Type 2 Diabetes Mellitus with a BMI < 35 kg/m²: A Hyperglycemic Clamp Validated Study. *Medicina (Kaunas)*. 2022;58:876. [\[Crossref\]](#)
30. Nayak SS, Kuriyakose Di, Polisetty LD, Patil AA, Ameen D, Shetty SP, et al. Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis. *Cardiovasc Diabetol*. 2024;23:310. [\[Crossref\]](#)
31. Zhang F, Hou X. Association between the triglyceride glucose index and heart failure: NHANES 2007-2018. *Front Endocrinol (Lausanne)*. 2024;14:1322445. [\[Crossref\]](#)
32. Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2022;21:124. [\[Crossref\]](#)